Gilteritinib
Xospata
Near Add Your Location
Accepting patients
ASTX727, Venetoclax, and Gilteritinib
A Phase I/II Study of ASTX727, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome With an Activating FLT3 Mutation
- BCL-2 Inhibitor
- Cytidine Deaminase Inhibitor
- Nucleoside Metabolic Inhibitor
- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
Accepting patients
Azacitidine, Venetoclax, and Gilteritinib
A Phase I/II Study of Azacitidine, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome With an Activating FLT3 Mutation
- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
Accepting patients
Chemotherapy Plus Venetoclax
Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML
- BCL-2 Inhibitor
- Kinase Inhibitor
- Tyrosine Kinase (TK) Inhibitor
- Phase 2
Accepting patients
MyeloMATCH Master Protocol
Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
- Genetic Sequencing
- Phase 2